Familial Pancreatic Cancer

Helena Saba¹, Michael Goggins²

Affiliations

¹ Departments of Pathology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA.
² Departments of Pathology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Departments of Medicine, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Departments of Oncology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Bloomberg School of Public Health, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA. Electronic address: mgoggins@jhmi.edu.

PMID: 36153110
PMCID: PMC11095833
DOI: 10.1016/j.gtc.2022.06.006

Review

Familial Pancreatic Cancer

Helena Saba et al. Gastroenterol Clin North Am. 2022 Sep.

. 2022 Sep;51(3):561-575.

doi: 10.1016/j.gtc.2022.06.006. Epub 2022 Aug 29.

Authors

Helena Saba¹, Michael Goggins²

Affiliations

¹ Departments of Pathology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA.
² Departments of Pathology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Departments of Medicine, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Departments of Oncology, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA; Bloomberg School of Public Health, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, CRB2 351, 1550 Orleans Street, Baltimore, MD 21231, USA. Electronic address: mgoggins@jhmi.edu.

PMID: 36153110
PMCID: PMC11095833
DOI: 10.1016/j.gtc.2022.06.006

Abstract

Individuals at increased risk of developing pancreatic cancer, including those with a significant family history of the disease and those with pancreatic cancer susceptibility gene variants, can benefit from pancreas surveillance. Most pancreatic cancers diagnosed during surveillance are early-stage and such patients can achieve long-term survival. Determining who should undergo pancreas surveillance is still a work-in-progress, but the main tools clinicians use to estimate an individual's risk of pancreatic cancer are patient's age, the extent of their family history of pancreatic cancer, and whether or not they have a pancreatic cancer susceptibility gene mutation.

Keywords: Familial; Hereditary; Pancreas surveillance; Pancreatic cancer; Screening.

PubMed Disclaimer

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. - PubMed
1. Rahib L, Wehner MR, Matrisian LM, et al. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 2021;4(4):e214708. - PMC - PubMed
1. Biller LH, Wolpin BM, Goggins M. Inherited pancreatic cancer syndromes and high-risk screening. Surg Oncol Clin N Am 2021;30(4):773–86. - PMC - PubMed
1. Meza R, Jeon J, Moolgavkar SH, et al. Age-specific incidence of cancer: Phases, transitions, and biological implications. Proc Natl Acad Sci U S A 2008;105(42):16284–9. - PMC - PubMed
1. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020;69(1):7–17. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Familial Pancreatic Cancer

Affiliations

Familial Pancreatic Cancer

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical